Introduction {#sec1-1}
============

Chronic myeloid leukemia (CML) is a stem cell clonal disease characterized by the acquisition of a fusion protein, *BCR-ABL1* oncogene, which leads to uncontrolled proliferation of myeloid elements in all stages of differentiation \[**[@R1]**,**[@R2]**\]. The fusion gene is the result of reciprocal translocation (9;22)(q34;q11) known as Philadelphia (Ph) chromosome, discovered by Nowell and Hungerford in 1960 \[**[@R3]**-**[@R5]**\]. CML is a multiphase disease, which may be diagnosed in three distinct phases: chronic phase (CP), accelerated phase (AP) and blast phase known as blast crisis (BP). Most patients are diagnosed in CP \[**[@R6]**\].

CML is the first neoplasm in which the knowledge of molecular lesion has enabled the discovery of targeted therapies. Imatinib mesylate, the first generation of *BCR-ABL1* tyrosine kinase inhibitor (TKI), optimized disease treatment and increased overall survival (OS) from fatal within 3-5 years since diagnosis to a life expectancy of 20 years. During theTKI era, protocols for assessing response and resistance to treatment were developed. Once TKI were established as standard treatment for CML, eight years phase III IRIS trial demonstrated that Imatinib induced a complete cytogenetic response (CCyR) in 87% of the patients with an estimated long-term overall survival (OS) of 85% \[**[@R7]**\]. The latest results reported that 17% of the patients did not achieve a cytogenetic response (primary resistance) while 15% of the patients lost the obtained response (secondary resistance). Overall, Imatinib did not obtain optimal results in 40% of the patients \[**[@R7]**\]. During the Imatinib treatment, the monitoring of clonal evolution proved to be very important. The long term monitoring results indicated that most events such as resistance and/ or progression occurred in the first three years, highlighting the importance of regular monitoring in this phase of treatment \[**[@R7]**\]. One important conclusion of IRIS trial was that the achievement of CCyR within the first 12 months of treatment is associated with long-term optimal response \[**[@R7]**\]. Currently, the only feature correlated with the treatment failure is the presence of additional chromosomal abnormalities (ACAs) which were observed in 5 to 10% CML patients diagnosed in CP.

Materials and methods {#sec1-2}
=====================

The study was conducted in accordance with the applicable regulatory requirements. The protocol was approved by the institutional review board and ethics committee of the participating centre. All the patients gave a written informed consent before participation.

The observational retrospective study collected data from the Hematology and Bone Marrow Transplantation Department of Fundeni Clinical Institute, Bucharest. During 2005 until 2013, 199 CML patients were diagnosed and monitored. In this single centre study, 28 (14.07%) CML patients with ACAs at diagnosis (group A) and during TKI (group B) were included. The aim of this study was to analyze the impact of ACAs on time to achieve CCyR, treatment and overall survival.

CML was confirmed by fluorescence in situ hybridization (FISH) study for BCR-ABL1 of blood interphase cell nuclei followed by chromosome banding analysis (CBA).

Fluorescence in situ hybridization (FISH) study for BCR (22q11.23)/ ABL (9q34) used Dual Color ON BCR/ ABL translocation probe, BCR was marked with green (G) and ABL with red (R). Expected signals patterns: negative 2R 2G (normal) and positive (standard): 1R 1G 2F (presence of BCR/ ABL translocation). The exam analyzed blood interphase nuclei and not metaphases.

Fresh bone marrow samples were obtained. Samples were prepared by using overnight and cell cycle synchronization cultures and were analyzed by using GTG chromosome banding analysis (CBA) \[**[@R14]**\]. At least 20 metaphases were analyzed. The karyotype was described according to International System for Human Cytogenetic Nomenclature (ISCN) 2009 \[**[@R15]**\].

According to the European LeukemiaNet (ELN) recommendations, the cytogenetic response (CyR) was evaluated at month 3 and 6 of the TKI treatment, every 6 months until CCyR, every 12 months since CCyR and at any time on a clinical suspicion of progression \[**[@R21]**\].

Results {#sec1-3}
=======

During 2005-2013, 199 CML patients were diagnosed and monitored in our centre. Only 28 (14.07%) CML patients with ACAs at diagnosis and during TKIs were reported. The median age of patients was 50.5 years. EUTOS recommendations at the patient's enrolment were first generation TKI (Imatinib) with a different dose according to phase and risk or inclusion in clinical trials.

In the study, we evaluated 11 (5.52%) patients with ACAs at diagnosis (group A) and 17 (8.54%) patients with ACAs during the TKI treatment (group B).

###### 

Characteristics of patients in group A and B

  ------------------------------------------------ ------------- ---------------- ----------------
  Parameters                                                     Group A (N=11)   Group B (N=17)
  Males                                                          7                8
  Females                                                        4                9
  Median age (years)                                             51.72 (32-75)    49.70 (25-71)
  CML-CP                                                         9                17
  CML-AP                                                         2                0
  EUTOS score                                      low           9 (81.81 %)      16 (94.11 %)
                                                   high          2 (18.18 %)      1 (5.88 %)
  Cytogenetic abnormalities in Ph positive cells   minor route   8 (4.01 %)       4 (2 %)
                                                   major route   3 (1.50 %)       5 (2.51 %)
  Cytogenetic abnormalities in Ph negative cells   minor route   0 (0 %)          5 (2.51 %)
                                                   major route   0 (0 %)          3 (1.50 %)
  ------------------------------------------------ ------------- ---------------- ----------------

In group A, 11 (5.52%) patients were included. Nine patients were in CP and two patients in AP. Retrospective EUTOS score were low in all CP patients. Nine patients received Imatinib and two patients Nilotinib. During follow-up, one patient was in lymphoid BP, two patients in AP, and eight patients in CP according to ELN recommendations.

The patient in lymphoid BP received induction therapy but died due to disease progression, two patients in AP received Dasatinib and eight patients in CP received as it follows: two patients maintained Nilotinib and six patients received Imatinib. The median time to CCyR was of 20 months. At the study's end according to ELN recommendations, 9 patients were in CCyR, 1 patient received allogeneic hematopoietic stem cell transplant (HSCT) from unrelated HLA matched donor and 1 death was reported.

###### 

Characteristics of patients in group A

  --------- ------------------------ -------------------------- ------------------ ----------------------- --------------------- -------------------------------------- --------------------------
  Pts no.   CML phase at diagnosis   CML phase at progression   TKI at diagnosis   TKI after progression   TKI at study\`s end   Cytogenetic response at study\`s end   Survival at study\`s end
  1         AP                       CP                         IMA600             IMA400                  IMA400                CCyR                                   yes
  2         CP                       AP                         IMA400             DASA 140                DASA 140              CCyR                                   yes
  3         CP                       CP                         IMA400             IMA400                  IMA400                CCyR                                   yes
  4         CP                       CP                         NILO600            NILO600                 NILO600               CCyR                                   yes
  5         CP                       AP                         IMA400             DASA 140                allogeneic HSCT       CCyR                                   yes
  6         CP                       lymphoid BP                IMA400             N/A                     induction therapy     N/A                                    no
  7         CP                       CP                         IMA400             IMA400                  IMA400                CCyR                                   yes
  8         CP                       CP                         IMA600             IMA400                  IMA400                CCyR                                   yes
  9         AP                       CP                         IMA600             IMA400                  IMA400                CCyR                                   yes
  10        CP                       CP                         NILO600            NILO600                 NILO600               CCyR                                   yes
  11        CP                       CP                         IMA400             IMA400                  IMA400                CCyR                                   yes
  --------- ------------------------ -------------------------- ------------------ ----------------------- --------------------- -------------------------------------- --------------------------

Of eleven patients, eight expressed minor route ACAs and three expressed major route ACAs. The most frequent minor route cytogenetic abnormalities in Ph positive cells were monosomies and structural abnormalities (inversions and translocations). The most frequent major route cytogenetic abnormalities in Ph positive cells were trisomy 8 (27.27%), trisomy 19 (9.09%) and second Philadelphia chromosome (9.09%). No minor route abnormalities of chromosome 7 in Ph negative cells were identified.

###### 

Karyotype of patients in group A according to 2009 ISCN recommendations

  --------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pts no.   Karyotype at diagnosis
  1         46,XY,t(9;22)(q33;q11)\[13\]/46,XY,t(9;22)(q34;q11),-15,+19\[5\]/ 52,XY,t(9;22)(q34;q11),+8,+12,+13,+14,+19,+20\[4\]
  2         46,XX,t(9;22)(q34;q11)\[12\]/45,X,-X,t(9;22)(q34;q11)\[4\]/46,XX\[6\]
  3         46,XY\[16\]/46,XY,t(9;22)(q34;q11)\[8\]/44,XY,t(9;22)(q34;q11),-15,-19\[3\];
  4         46,XY,t(9;22)(q34;q11)\[2\]/46,XY,t(9;22)(q34;q11),inv(1)(p?;q?)\[13\]/46,XY\[5\];
  5         46,XY,t(9;22)(q34;q11)\[15\]/46,XY,t(1;9;22)(q?;q34;q11)\[7\];
  6         46, XX,t(9;22)(q34;q11)\[8\]/45,X,-X,t(9;22)(q34;q11)\[4\]/46,XX\[9\];
  7         46,XX,t(9;22)(q34;q11),t(2;7)(q21;q22)\[18\]/ 46,XX\[4\]
  8         46,XY,t(9;22)(q34;q11),t(12;14)(q22;q24)\[8\]/47,XY,t(9;22)(q34;q11),t(12;14) (q22;q24),+8\[2\]/48,XY,t(9;22)(q34;q11),t(12;14)(q22;q24),+8,+der(22)t(9;22)\[10\]
  9         46,XX,t(9;22)(q34;q11)\[19\]/97,idemx2,+der(22)(q34;q11)\[3\]
  10        46,XY,t(9;22)(q34;q11)\[21\]/45,X,-Y,t(9;22)(q34;q11)\[4\]/46,XY\[9\]
  11        46,XY,t(9;22)(q34;q11)\[19\]/45,X,-Y,t(9;22)(q34;q11)\[3\]/46,XY\[5\]
  --------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------

In group B, 17 (8.54%) patients were included. All patients were in CP of CML at diagnosis. The retrospective EUTOS score were low for 16 patients and high for 1 patient. All patients received Imatinib. The median duration of the TKI treatment until ACAs detection was of 36 months.

At the ACAs detection, 5 patients received Dasatinib and 11 patients Imatinib. The patients maintained Imatinib 400 mg daily due to intolerance to Dasatinib and higher dose Imatinib. One patient received a higher dose of Imatinib and Hydroxicarbamide due to intolerance to Dasatinib. For this patient, no related and unrelated HLA matched donors were available. At the time, Nilotinib was available as first line in clinical trials but not in second line.

During follow-up, one patient had progressed to myeloid BP, six patients in AP, and ten patients in CP according to ELN recommendations.

The patient in myeloid BP received induction therapy but died due to neutropenia complications, six patients received allogeneic hematopoietic stem cell transplant (HSCT) from unrelated HLA matched donor and ten patients maintained previous TKI treatment and achieved CCyR in a median time of 24 months.

At the study's end, according to ELN recommendations, ten patients were in CCyR, six patients received allogeneic hematopoietic stem cell transplant from unrelated HLA matched donors and one death was reported.

###### 

Characteristics of patients in group B

  --------- ------------------- -------------------------- ------------- ---------------------------- ---------------------------------------- ------------------------ -------------------------
  Pts no.   Initial CML phase   CML phase at progression   Initial TKI   TKI at progression           Cytogenetic response at ACAs detection   Treatment at study end   Survival at study's end
  1         CP                  myeloid BP                 IMA 400       N/A                          failure                                  induction                no
  2         CP                  AP                         IMA400        DASA140                      CCyR                                     DASA140                  yes
  3         CP                  AP                         IMA400        DASA100                      mCyR                                     allogeneic HSCT          yes
  4         CP                  AP                         IMA 400       IMA 600 + Hydroxicarbamide   mCyR                                     allogeneic HSCT          yes
  5         CP                  CP                         IMA 400       IMA 600                      CCyR                                     IMA 600                  yes
  6         CP                  CP                         IMA 400       IMA 400                      CCyR                                     IMA 400                  yes
  7         CP                  CP                         IMA 400       IMA 400                      CCyR                                     IMA 400                  yes
  8         CP                  CP                         IMA 400       IMA 400                      CCyR                                     IMA 400                  yes
  9         CP                  AP                         IMA 400       DASA100                      mCyR                                     allogeneic HSCT          yes
  10        CP                  AP                         IMA 400       DASA100                      mCyR                                     allogeneic HSCT          yes
  11        CP                  CP                         IMA400        IMA400                       CCyR                                     IMA 400                  yes
  12        CP                  CP                         IMA400        IMA600                       CCyR                                     IMA600                   yes
  13        CP                  CP                         IMA400        IMA400                       CCyR                                     IMA400                   yes
  14        CP                  CP                         IMA 400       IMA400                       CCyR                                     IMA 400                  yes
  15        CP                  AP                         IMA 400       DASA100                      PCyR                                     allogeneic HSC           yes
  16        CP                  AP                         IMA 400       DASA100                      PCyR                                     allogeneic HSC           yes
  17        CP                  CP                         IMA 400       IMA400                       CCyR                                     IMA 400                  yes
  --------- ------------------- -------------------------- ------------- ---------------------------- ---------------------------------------- ------------------------ -------------------------

Of 17 patients, 5 patients expressed major route ACAs, 3 patients expressed major route cytogenetic abnormalities in Ph negative cells, 4 patients expressed minor route ACAs and 5 patients expressed minor route cytogenetic abnormalities in Ph negative cells. The most frequent major route cytogenetic abnormalities in Ph positive and negative cells were trisomy 8, trisomy 19 and second Ph chromosome. The most frequent minor route cytogenetic abnormalities in Ph positive and negative cells were marker chromosomes and structural abnormalities (inversions, translocations, and dicentric chromosomes). No minor route abnormalities of chromosome 7 in Ph negative cells were identified.

###### 

Karyotype of patients in group B according to ISCN 2009 recommendations

  ---- ------------------------- -----------------------------------------------------------------------------------------------------------------------
  Pt   TKI until ACAs (months)   Karyotype at ACAs detection
  1    60                        47,XX,+der(9),idic(22)t(9;22)(q43;q11)\[11\]/48,XX,+der(9),2idic(22)t(9;22)(q43;q11) \[2\]/47,XX,+19\[3\]/46,XX\[4\];
  2    24                        46,XY\[21\]/46,XY,t(9;22)(q34;q11),inv(2)(p?;q?)\[2\]
  3    12                        46,XY\[15\]/46,XY,t(9;22)(q34;q11)\[4\]/47,XY,t(9;22)(q34;q11),+19\[3\]
  4    60                        46,XY,t(9;22)(q34;q11)\[16\]/44,XY,-21,-22\[5\]
  5    60                        46,XX\[22\]/46,XX,t(9;22)(q34;q11)\[1\]/45,XX,idem,-18\[3\]
  6    48                        46,XY\[23\]/47,XY,+mar\[3\]
  7    60                        46,XY\[17\]/47,XY,t(9;22)(q34;q11)+8\[3\]
  8    18                        46,XX\[19\];45,X,-X\[5\]
  9    24                        46,XY,t(9;22)(q34;q11)\[4\]/47,XY,t(9;22)(q34;q11),+der(22)t(9;22)\[12\]/46,XY\[4\]
  10   84                        46,XX,t(9;22)(q34;q11)\[26\]/47,XX,t(9;22)(q34;q11),+mar,+dm\[2\]/ 46,XX\[6\]
  11   24                        46,XX\[11\]/49,XX,+8,+19,+19\[4\]/ 49,XX,+8,+14,+19\[5\]
  12   24                        46,XY\[22\]/47,XY,+8\[3\]
  13   24                        46,XY\[18\];47,XY,+mar\[2\]
  14   12                        46,XX,t(9;22)(q34;q11)\[12\]/46,XX,t(9;22)(q34;q11),+8,-13\[4\]/45,XX,dic (3;17)(q?;p?)\[1\]/46,XX\[8\];
  15   12                        46,XY\[19\]/47,XY,t(9;22)(q34;q11),+mar\[4\]
  16   6                         46,XX\[16\];46XX,t(9;22)(q34;q11)\[10\];47,XX,t(9;22)(q34;q11),+19\[4\]
  17   60                        46,XX\[19\]/ 45,XX,-21\[4\]
  ---- ------------------------- -----------------------------------------------------------------------------------------------------------------------

Discussions {#sec1-4}
===========

The 2013 ELN recommendations suggest that the presence of ACAs at diagnosis is a warning signal. ACAs during the TKI treatment define TKI failure and are associated with shorter overall survival (OS) on second-line Imatinib \[after Interferon alpha (rIFNα) first line treatment\] but not second-line Dasatinib or Nilotinib. ACAs have been reported to have an adverse prognostic value, particularly in the case of major route abnormalities including trisomy 8, trisomy Ph (+der(22)t(9;22)(q34;q11)), isochromosome 17 (i(17)(q10)), trisomy 19 and ider(22)(q10)t(9;22)(q34;q11). High-risk and major route ACAs can help identify patients eligible for investigational approaches but in daily practice, they do not mandate different initial treatments. Major route ACAs developing during treatment were confirmed to be a signal of acceleration. Cytogenetic abnormalities in Ph negative cells occur in 5% to 10% of the patients and, in the absence of dysplasia, do not seem to adversely affect the outcome. The exception is abnormalities of chromosome 7 (monosomy 7 and del (7q)). Some case reports indicate a risk of myelodysplasia and acute leukemia and justify long-term follow-up bone marrow biopsies \[**[@R21]**\].

Two large studies have confirmed the prognostic impact of ACAs detection. An Italian Working Group study which evaluated 378 patients, detected the presence of ACAs in 21 (5.6%) patients for whom the time to achieve CCyR and major molecular response (MMR) were longer. Long-term results in patients with ACAs were inferior but the differences were not significant compared to standard CML patients \[**[@R8]**\]. A German working group study identified the presence of ACAs in 79 (6.9%) of 1151 enrolled and Imatinib treated patients. For those patients, the time to achieve CCyR and MMR was longer. Progression free (PFS) and overall survival (OS) were shorter than in patients with standard t (9; 22) \[**[@R9]**\].

The presence of ACAs at diagnosis and during TKI treatment may announce treatment failure and/ or transformation to advanced stage (accelerated or blast) \[**[@R10]**\]. ACAs can be divided into major route ACAs represented by trisomy 8 (+8), isochromosome (17q)\[i(17q)\], trisomy 19 (+19) and a second Philadelphia chromosome (+Ph) and minor route ACA represented by monosomy 7 (-7), monosomy 17 (-17), trisomy 21 (+21), loss of Y chromosome (-Y) and t (3; 21) (q26; q22) \[**[@R11]**,**[@R12]**\]. At least one of those abnormalities occurs in 15% of Philadelphia positive cells. Multiple cytogenetic abnormalities (numerical and structural) were associated with translocation (9;22). The most common chromosomal abnormalities are represented by trisomy 8 (+8) (34%), second Philadelphia chromosome (+ Ph) (30%), isochromosome (17q) (17q) (20%), trisomy 19 (+19) (13%), loss of Y chromosome (-Y) (8%), trisomy 21 (+21) (7%), monosomy 17 (-17) (5%) and monosomy 7 (-7) (5%) \[**[@R13]**\]. Clonal evolution in CML is a marker of progression and represents chromosomal instability \[**[@R16]**\]. Shortening of telomere length is frequently associated with disease progression and may be a factor involved in chromosomal instability as telomere length is an important factor in chromosome integrity \[**[@R16]**\].

###### 

Patterns of additional chromosomal abnormalities in CML

  ---------------------------------------- --------------------------------------------------------
  Chronic phase (according to frequency)   Accelerated and blastic phase (according to frequency)
  classic +Ph                              classic +Ph
  variant +Ph                              variant +Ph
  +Ph, +8                                  +Ph, +8
  +Ph, -Y                                  +Ph, -Y
  +Ph, -21                                 +Ph, i(17q)
  +8                                       +19/ +17/ -7
  complex karyotype                        complex karyotype
  ---------------------------------------- --------------------------------------------------------

From 11 (5.52%) patients in group A, eight expressed minor route ACAs and three expressed major route ACAs. The most frequent minor route ACAs were monosomies and structural abnormalities (inversions and translocations). The most frequent major route ACAs cells were trisomy 8 (27.27%), trisomy 19 (9.09%) and second Philadelphia chromosome (9.09%). Our results are similar to those published in the literature \[**[@R9]**,**[@R17]**\]. Major route ACAs discovered at diagnosis may alert to early progression to advanced phase (accelerated or blast) and are important for assessing time to CCyR. Minor route ACAs have not yet proved important for progression \[**[@R18]**\].

From 17 (8.54%) patients in group B, 5 patients expressed major route ACAs, 3 patients expressed major route cytogenetic abnormalities in Ph negative cells, 4 patients expressed minor route ACAs and 5 patients expressed minor route cytogenetic abnormalities in Ph negative cells. The most frequent major route cytogenetic abnormalities in Ph positive and negative cells were trisomy 8 (17.64%), trisomy 19 (11.76%) and second Ph chromosome (5.88%). The most frequent minor route cytogenetic abnormalities in Ph positive and negative cells were marker chromosomes and structural abnormalities (inversions, translocations, and dicentric chromosomes). The impact of cytogenetic abnormalities in Ph negative cells is still to be determined but they have been described in 2-17% of the patients on Imatinib \[**[@R19]**\]. This phenomenon is transient and the clinical impact is unclear \[**[@R20]**\].

In both groups, no minor route abnormalities of chromosome 7 in Ph negative cells were reported.

In our study, the median time to BP progression was of 40 months (8-72).

At the end of our study, from 28 patients enrolled, 19 patients were in long-term CCyR on TKI treatment, 7 patients received allogeneic hematopoietic stem cell transplant from unrelated donor and 2 deaths were reported. The 12 months follow up after the study's end showed that 26 patients are alive and in long-term CCyR. The time to CCyR was longer in both groups and long-term results in patients with ACAs were inferior compared to standard patients but the differences were not significant and in accordance to published.

Conclusions {#sec1-5}
===========

The presence of ACAs at diagnosis and during the TKI treatment may announce treatment failure and/ or transformation to advanced stage (accelerated or blast).

In our study, the cytogenetic response is heterogeneous. The time to CCyR was longer in both groups and long-term results in patients with ACAs were inferior, but the differences were not significant and in accordance to published data. The follow up after the study's end showed that 26 patients are alive and in long-term CCyR: 19 patients were in long-term CCyR on TKI treatment, 7 patients received allogeneic hematopoietic stem cell transplant from unrelated donor and 2 deaths were reported.

The detection of ACAs during the TKI treatment is a warning sign of disease progression and periodic cytogenetic monitoring is mandatory, allowing real time therapeutic intervention (second generation of TKI or allogeneic hematopoietic stem cell transplant).

In this study, we demonstrated the importance of cytogenetic monitoring for the detection of disease progression and early TKI treatment switch or allogeneic stem cell transplantation.
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